Porous polyethylene for tissue engineering applications in diabetic rats treated with calcitonin: histomorphometric analysis.
OBJECTIVE
The purpose of this work was to study the bone tissue reaction after porous polyethylene (Polipore) implantation into surgical defects in the parietal bones of rats with streptozotocin-induced diabetes, treated with salmon calcitonin.


METHODS
Porous polyethylene implants were placed in bone defects created in 36 adult female rats. The rats were divided into 3 equal groups: diabetic treated with calcitonin (DCa), diabetic (D), and control (C). The animals of the DCa group received applications of salmon calcitonin on alternating days immediately after the surgery until sacrifice. The rats were sacrificed after 15, 30, 60, and 90 days, and the defects were examined histologically and statistically through histomorphometric analysis.


RESULTS
Histomorphometric analysis showed that there was no statistically significant difference in the mean quantity of inflammatory cells among all study groups after 15 and 90 days. At 30 days, a statistically significant difference was observed between the D and C groups and the D and DCa groups. At 60 days, there was no statistically significant difference between the D and DCa groups.


CONCLUSIONS
Porous polyethylene can be considered an option for implant material when there are investigations that prove its biocompatibility and stability in the host tissues. Salmon calcitonin positively aided the bone repair and attenuated the inflammatory response until 30 days after the surgery.


CONCLUSIONS
Porous polyethylene was tolerated by the host tissues in all groups, and moderate chronic inflammatory reaction was observed up to the 90-day period. Salmon calcitonin attenuated the inflammatory response up until 30 days.
Claro
Flávio Augusto
FA
flavioaclaro@bol.com.br
Lima
José Roberto Sá
JR
Salgado
Miguel Angel Castillo
MA
Gomes
Mônica Fernandes
MF
D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry / Q000627:therapeutic use; D001847:Bone Diseases / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D018786:Bone Substitutes / Q000737:chemistry / Q000627:therapeutic use*; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use*; D003238:Connective Tissue / Q000473:pathology; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D005260:Female; D015726:Giant Cells / Q000473:pathology; D006097:Granulation Tissue / Q000473:pathology; D007279:Injections, Subcutaneous; D008214:Lymphocytes / Q000473:pathology; D008264:Macrophages / Q000473:pathology; D010294:Parietal Bone / Q000187:drug effects / Q000473:pathology; D020959:Polyethylene / Q000737:chemistry / Q000627:therapeutic use*; D016062:Porosity; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D013997:Time Factors; D023822:Tissue Engineering / Q000379:methods*; D014945:Wound Healing / Q000187:drug effects
D001672:Biocompatible Materials; D018786:Bone Substitutes; D013311:Streptozocin; D020959:Polyethylene; D002116:Calcitonin